Works by Leiba, Merav

Results: 44
    1

    Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib.

    Published in:
    EJHaem, 2020, v. 1, n. 1, p. 1, doi. 10.1002/jha2.4
    By:
    • Richardson, Paul G.;
    • Nagler, Arnon;
    • Ben-Yehuda, Dina;
    • Badros, Ashraf;
    • Hari, Parameswaran N.;
    • Hajek, Roman;
    • Spicka, Ivan;
    • Kaya, Hakan;
    • LeBlanc, Richard;
    • Sung-Soo Yoon;
    • Kihyun Kim;
    • Martinez-Lopez, Joaquin;
    • Moshe Mittelman;
    • Shpilberg, Ofer;
    • Blake, Paul;
    • Teru Hideshima;
    • Colson, Kathleen;
    • Laubach, Jacob P.;
    • Ghobrial, Irene M.;
    • Leiba, Merav
    Publication type:
    Article
    2
    3
    4

    Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapy.

    Published in:
    Palliative Medicine, 2021, v. 35, n. 5, p. 927, doi. 10.1177/02692163211000634
    By:
    • Barki-Harrington, Liza;
    • Baron-Epel, Orna;
    • Shaulov, Adir;
    • Akria, Luiza;
    • Barshay, Yossef;
    • Dally, Najib;
    • Deshet, Dana;
    • Inbar, Tsofia;
    • Koren-Michowitz, Maya;
    • Leiba, Merav;
    • Moshe, Yakir;
    • Shvidel, Lev;
    • Tadmor, Tamar;
    • Yagenah, Shai;
    • Zektser, Miri;
    • Preis, Meir;
    • Hellman, Ilana;
    • Yahalom, Vered;
    • Aviv, Ariel
    Publication type:
    Article
    5
    6
    7
    8

    Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.

    Published in:
    Blood Cancer Journal, 2020, v. 10, n. 11, p. 1, doi. 10.1038/s41408-020-00375-2
    By:
    • Kaufman, Jonathan L.;
    • Dimopoulos, Meletios A.;
    • White, Darrell;
    • Benboubker, Lotfi;
    • Cook, Gordon;
    • Leiba, Merav;
    • Morton, James;
    • Joy Ho, P.;
    • Kim, Kihyun;
    • Takezako, Naoki;
    • Moreau, Philippe;
    • Sutherland, Heather J.;
    • Magen, Hila;
    • Iida, Shinsuke;
    • Kim, Jin Seok;
    • Miles Prince, H.;
    • Cochrane, Tara;
    • Oriol, Albert;
    • Bahlis, Nizar J.;
    • Chari, Ajai
    Publication type:
    Article
    9
    10
    11
    12
    13
    14

    Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 14, p. 3448, doi. 10.1080/10428194.2022.2118535
    By:
    • Ganzel, Chezi;
    • Trestman, Svetlana;
    • Levi, Shai;
    • Gatt, Moshe E.;
    • Lavi, Noa;
    • Vaxman, Iuliana;
    • Rouvio, Ory;
    • Magen, Hila;
    • Lebel, Eyal;
    • Horowitz, Netanel A.;
    • Leiba, Merav;
    • Tadmor, Tamar;
    • Herzog Tzarfati, Katrin;
    • Surio, Celia;
    • Yeganeh, Shay;
    • Dally, Nagib;
    • Avivi, Irit;
    • Cohen, Yael C.
    Publication type:
    Article
    15

    Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.

    Published in:
    Leukemia & Lymphoma, 2021, v. 62, n. 1, p. 118, doi. 10.1080/10428194.2020.1824069
    By:
    • Segman, Yafit;
    • Ribakovsky, Elena;
    • Avigdor, Abraham;
    • Goldhecht, Yair;
    • Vainstein, Vladimir;
    • Goldschmidt, Neta;
    • Harlev, Shimrit;
    • Horwitz, Netanel;
    • Gutwein, Odit;
    • Gurion, Ronit;
    • Itchaki, Gilad;
    • Abadi, Uri;
    • Nemets, Anatoly;
    • Sofer, Orit;
    • Zektser, Miri;
    • Tadmor, Tamar;
    • Dally, Nagib;
    • Filanovsky, Kalman;
    • Leiba, Merav;
    • Sarid, Nadav
    Publication type:
    Article
    16
    17
    18
    19

    Cytogenetics of extramedullary manifestations in multiple myeloma.

    Published in:
    British Journal of Haematology, 2013, v. 161, n. 1, p. 87, doi. 10.1111/bjh.12223
    By:
    • Billecke, Lisa;
    • Murga Penas, Eva M.;
    • May, Annette M.;
    • Engelhardt, Monika;
    • Nagler, Arnon;
    • Leiba, Merav;
    • Schiby, Ginette;
    • Kröger, Nicolaus;
    • Zustin, Jozef;
    • Marx, Andreas;
    • Matschke, Jakob;
    • Tiemann, Markus;
    • Goekkurt, Eray;
    • Heidtmann, Hans‐Heinrich;
    • Vettorazzi, Eik;
    • Dierlamm, Judith;
    • Bokemeyer, Carsten;
    • Schilling, Georgia
    Publication type:
    Article
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32

    Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.

    Published in:
    British Journal of Haematology, 2023, v. 200, n. 1, p. 45, doi. 10.1111/bjh.18479
    By:
    • Shragai, Tamir;
    • Magen, Hila;
    • Lavi, Noa;
    • Gatt, Moshe;
    • Trestman, Svetlana;
    • Zektser, Miri;
    • Ganzel, Chezi;
    • Jarchowsky, Osnat;
    • Berger, Tamar;
    • Tadmor, Tamar;
    • Leiba, Merav;
    • Hertzog‐Tzarfaty, Katrin;
    • Horowitz, Netanel;
    • Shapira, Michael;
    • Varssano, David;
    • Berger, Yoav;
    • Frenkel, Shahar;
    • Krauthammer, Mark;
    • Avivi, Irit;
    • Luttwak, Efrat
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39
    40

    High-dimensional Clonal Heterogeneity and Immune Landscape in Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e28, doi. 10.1016/j.clml.2019.09.042
    By:
    • Jakubikova, Jana;
    • Cholujova, Danka;
    • Beke, Gabor;
    • Hunter, Zachary;
    • Hideshima, Teru;
    • Leiba, Merav;
    • Jamroziak, Krzysztof;
    • Richardson, Paul G.;
    • Kastritis, Efstathios;
    • Dorfman, David M.;
    • Anderson, Kenneth C.
    Publication type:
    Article
    41

    Daratumumab, Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM Based on Prior Lines and Treatment Exposure: POLLUX.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e116, doi. 10.1016/j.clml.2017.03.211
    By:
    • Dimopoulos, Meletios;
    • Belch, Andrew R.;
    • White, Darrell J.;
    • Benboubker, Lofti;
    • Cook, Gordon;
    • Leiba, Merav;
    • Morton, James;
    • Ho, P. Joy;
    • Kim, Kihyun;
    • Takezako, Naoki;
    • San-Miguel, Jesus;
    • Moreau, Philippe;
    • Kaufman, Jonathan L.;
    • Sutherland, Heather;
    • Lalancette, Marc;
    • Magen, Hila;
    • Iida, Shinsuke;
    • Kim, Jin Seok;
    • Prince, H. Miles;
    • Cochrane, Tara
    Publication type:
    Article
    42

    Depth of Response and MRD with Daratumumab Plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: POLLUX.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e17, doi. 10.1016/j.clml.2017.03.029
    By:
    • San-Miguel, Jesus;
    • Dimopoulos, Meletios Athanasios;
    • Usmani, Saad;
    • Belch, Andrew R.;
    • Bahlis, Nizar J.;
    • White, Darrell J.;
    • Benboubker, Lofti;
    • Cook, Gordon;
    • Leiba, Merav;
    • Morton, James;
    • Ho, P. Joy;
    • Kim, Kihyun;
    • Takezako, Naoki;
    • Kaufman, Jonathan L.;
    • Sutherland, Heather;
    • Lalancette, Marc;
    • Magen, Hila;
    • Iida, Shinsuke;
    • Kim, Jin Seok;
    • Prince, H. Miles
    Publication type:
    Article
    43
    44